Breaking News Instant updates and real-time market news.

BIIB

Biogen

$313.03

7.25 (2.37%)

10:16
10/03/16
10/03
10:16
10/03/16
10:16

Biogen potential trading opportunity into year-end, says BMO Capital

BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.

  • 26

    Oct

  • 06

    Nov

BIIB Biogen
$313.03

7.25 (2.37%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.

TODAY'S FREE FLY STORIES

ESPR

Esperion

$77.20

2.24 (2.99%)

05:06
01/22/18
01/22
05:06
01/22/18
05:06
Downgrade
Esperion rating change  »

Esperion downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$21.52

-0.58 (-2.62%)

05:02
01/22/18
01/22
05:02
01/22/18
05:02
Recommendations
Valeant analyst commentary  »

Valeant selloff Friday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

WP

Worldpay

$78.73

-0.35 (-0.44%)

04:57
01/22/18
01/22
04:57
01/22/18
04:57
Recommendations
Worldpay analyst commentary  »

Worldpay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$46.93

0.46 (0.99%)

, QGEN

Qiagen

$32.87

0.31 (0.95%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Recommendations
Quidel, Qiagen analyst commentary  »

Quidel price target…

QDEL

Quidel

$46.93

0.46 (0.99%)

QGEN

Qiagen

$32.87

0.31 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

MCO

Moody's

$159.18

1.6 (1.02%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

SANM

Sanmina

$35.45

0.5 (1.43%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Sanmina to hold a conference call »

Management holds an…Webcast Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

JAGX

Jaguar Health

$0.16

-0.0169 (-9.83%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…Webcast Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

$29.40

-0.16 (-0.54%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

BNED

Barnes & Noble Education

$7.70

0.25 (3.36%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

LLEX

Lilis Energy

$4.99

-0.12 (-2.35%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Lilis Energy management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 31

    Jan

NAVG

Navigators

$49.65

0.4 (0.81%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Navigators management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 16

    Feb

PETS

PetMed Express

$53.24

2.67 (5.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

December Chicago Fed…

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

ADP

ADP

$121.44

0.54 (0.45%)

, CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Stephens enterprise software analyst holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$121.44

0.54 (0.45%)

CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

ORCL

Oracle

$50.58

0.35 (0.70%)

PAYC

Paycom

$91.19

2.07 (2.32%)

PCTY

Paylocity

$49.99

0.33 (0.66%)

SAP

SAP

$113.20

1.53 (1.37%)

ULTI

Ultimate Software

$227.99

-0.84 (-0.37%)

WDAY

Workday

$114.11

0.83 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

IVC

Invacare

$16.91

0.26 (1.56%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 08

    Feb

PAYC

Paycom

$91.19

2.07 (2.32%)

, ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

$91.19

2.07 (2.32%)

ALRM

Alarm.com

$38.73

-0.7 (-1.78%)

CA

CA Technologies

$34.07

-0.12 (-0.35%)

RHT

Red Hat

$125.94

0.47 (0.37%)

ORCL

Oracle

$50.58

0.35 (0.70%)

SSNC

SS&C

$49.98

0.04 (0.08%)

VMW

VMware

$136.04

0.41 (0.30%)

CTXS

Citrix

$92.72

1.34 (1.47%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

SYMC

Symantec

$27.46

0.21 (0.77%)

PANW

Palo Alto Networks

$157.22

-0.6 (-0.38%)

APTI

Apptio

$24.79

0.56 (2.31%)

CHKP

Check Point

$104.48

1.28 (1.24%)

NICE

Nice

$93.60

-0.23 (-0.25%)

SPLK

Splunk

$89.94

-1.49 (-1.63%)

RNG

RingCentral

$54.15

0.95 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

HAL

Halliburton

$53.01

0.65 (1.24%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: Halliburton has a potential bullish pattern »

There is a potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HPQ

HP Inc.

$23.70

0.41 (1.76%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
HP Inc. to hold a webcast »

Global Head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

KMG

KMG Chemicals

04:52
01/22/18
01/22
04:52
01/22/18
04:52
Initiation
KMG Chemicals initiated  »

KMG Chemicals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 16

    Feb

KCDMY

Kimberly-Clark de Mexico

$9.44

0.05 (0.53%)

04:51
01/22/18
01/22
04:51
01/22/18
04:51
Downgrade
Kimberly-Clark de Mexico rating change  »

Kimberly-Clark de Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.